UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 29, 2020

ENANTA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

Registrant’s Telephone Number, Including Area Code: (617) 607-0800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Mark G. Foletta to Board of Directors

On June 29, 2020, the Board of Directors of Enanta Pharmaceuticals, Inc. announced that Mark G. Foletta had been elected to serve as an independent director of the company in the class of directors whose terms expire at Enanta’s 2022 annual meeting of stockholders. This election increases the number of directors to seven. The Board of Directors also appointed Mr. Foletta to be Chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee of the Board of Directors. Mr. Foletta will receive the standard cash compensation for non-employee directors of Enanta, including retainer fees for Board and committee service. In addition, he received a stock option to purchase 17,000 shares of Enanta’s Common Stock, which will vest over 36 months. Mr. Foletta will also have the benefit of Enanta’s standard form of indemnification agreement for non-employee directors.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

2